enstilar húðfroða 50 míkróg/0,5 mg/g
leo pharma a/s* - calcipotriolum inn; betamethasonum díprópíónat - húðfroða - 50 míkróg/0,5 mg/g
kairasec tafla 32 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 32 mg
oracea hart hylki með breyttan losunarhraða 40 mg
galderma nordic ab - doxycyclinum inn - hart hylki með breyttan losunarhraða - 40 mg
sativex munnholsúði, lausn 27 mg/ml + 25 mg/ml
jazz pharmaceuticals ireland ltd - delta-9-tetrahydrocannabinolum; cannabidiolum inn - munnholsúði, lausn - 27 mg/ml + 25 mg/ml
valsartan jubilant filmuhúðuð tafla 160 mg
jubilant pharmaceuticals nv - valsartanum inn - filmuhúðuð tafla - 160 mg
ebglyss
almirall, s.a. - lebrikizumab - dermatitis, atópísk - aðrar húðsjúkdómar - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
rivastigmine teva forðaplástur 4,6 mg/24 klst.
teva b.v.* - rivastigminum inn - forðaplástur - 4,6 mg/24 klst.
rivastigmine teva forðaplástur 9,5 mg/24 klst.
teva b.v.* - rivastigminum inn - forðaplástur - 9,5 mg/24 klst.